688526 科前生物
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)5.5019.83310.79912.31619.473
总资产报酬率 ROA (%)4.8488.3428.73810.09216.698
投入资产回报率 ROIC (%)5.2159.0199.52111.17218.440

边际利润分析
销售毛利率 (%)67.28363.75672.09373.61179.805
营业利润率 (%)52.07246.59143.14846.61259.927
息税前利润/营业总收入 (%)45.64439.97736.76840.26753.972
净利润/营业总收入 (%)44.99940.50137.17640.86351.734

收益指标分析
经营活动净收益/利润总额(%)90.60489.957112.82199.50298.501
价值变动净收益/利润总额(%)6.6418.5822.0411.7350.777
营业外收支净额/利润总额(%)-0.066-0.163-0.339-0.023-0.144

偿债能力分析
流动比率 (X)5.7165.3363.3844.1053.578
速动比率 (X)5.3875.0653.1933.8343.357
资产负债率 (%)11.37212.29617.84520.30715.339
带息债务/全部投入资本 (%)3.4602.7979.7289.0423.393
股东权益/带息债务 (%)2,733.1463,398.015910.127970.4822,777.643
股东权益/负债合计 (%)779.068712.912460.132392.198551.875
利息保障倍数 (X)-7.139-6.115-5.897-6.356-9.197

营运能力分析
应收账款周转天数 (天)116.072127.304110.821106.33968.653
存货周转天数 (天)151.709142.568190.461189.534145.359